{"entity":{"id":"catalym","kind":"company","name":"CatalYm","aka":["CatalYm GmbH"],"tldr":"CatalYm is a Germany-based biotechnology company running 5 late-stage cancer trials of Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma.","summary":"CatalYm, based in Planegg-Martinsried, Germany, is a biotechnology company. A private, venture-backed cancer immunotherapy company developing antibodies that neutralise GDF-15, a mechanism cancers use to resist treatment, with its lead candidate visugromab. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma. The largest, NCT07112196 (Visugromab in Cachexia International Trial), plans to enrol 518 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.catalym.com"},{"label":"ClinicalTrials.gov: trials led by CatalYm","url":"https://clinicaltrials.gov/search?lead=CatalYm%20GmbH"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["visugromab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07219459","nct07098988","nct07246863","nct04725474"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Planegg-Martinsried","country":"DE","companyType":"biotech","website":"https://www.catalym.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/catalym/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/"}],"trial":[{"id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/"},{"id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/"},{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/"},{"id":"nct07112196","kind":"trial","name":"Visugromab in Cachexia International Trial","route":"/trials/nct07112196/"},{"id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/"}]}}